查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980061

更年期支持市場預測至2034年：按支持類型、症狀類型、給藥途徑、劑型、最終用戶、分銷管道和地區分類的全球分析

Menopause Support Market Forecasts to 2034 - Global Analysis By Support Type, Symptom Type, Route of Administration, Dosage Form, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的研究，預計到 2026 年，全球更年期支持市場將達到 183 億美元，並在預測期內以 7.2% 的複合年成長率成長，到 2034 年達到 320 億美元。

更年期支持產品包括藥物、膳食補充劑和治療性給藥系統，旨在緩解閉經和更年期相關症狀，例如潮熱、情緒波動和陰道萎縮。該市場透過多種給藥途徑和劑型滿足老年女性日益成長的健康需求。人們對更年期管理的認知不斷提高，以及圍繞這一人生階段的討論不再那麼令人羞恥，正在推動產品創新，並擴大全球醫療保健系統中治療的可及性。

全球老年女性人口數量增加

人口結構的變化導致全球45-60歲女性人口顯著成長，從而擴大了更年期支持解決方案的潛在市場。隨著預期壽命的延長，女性如今約有三分之一的人生處於停經後階段，因此人們更加關注這段時期的生活品質。醫療保健系統也日益認知到，更年期並非不可避免的老化過程，而是需要全面管理的醫學問題。這種人口結構的變化，加上成熟消費者可支配收入的增加，正在催生對能夠緩解症狀和維護長期健康的藥物和天然支持產品的持續需求。

社會歧視和症狀報告不足

圍繞更年期的文化禁忌持續阻礙女性與醫療專業人員之間的公開對話，並限制市場成長。許多女性默默忍受更年期症狀，要么不了解可用的治療方法，要么因為羞於啟齒而猶豫尋求醫療幫助。這種溝通障礙導致診斷不足和治療不足的情況嚴重，尤其是在老化和女性健康問題仍然敏感的地區。更年期管理通常在醫療專業人員的培訓中得到充分解釋，這進一步加劇了治療率低下的問題。克服這些文化障礙需要持續進行針對全球不同市場消費者和醫療專業人員的宣傳活動。

個人化醫療與數位健康的融合

基因檢測和生物標記分析技術的進步使得基於個別症狀特徵和健康史的個人化更年期治療方案成為可能。提供症狀追蹤、遠端醫療諮詢和個人化營養補充劑推薦的數位健康平台，為尋求客製化解決方案的消費者開闢了新的互動管道。穿戴式裝置監測睡眠模式、皮膚溫度和心率變異性，為最佳化治療方案提供客觀數據。個人化醫療與數位工具的整合，使企業能夠與消費者建立直接聯繫，收集產品有效性的真實世界數據，並創建訂閱模式，確保在首次產品購買後仍能與客戶保持持續互動。

監管機構正在加強對生物同源激素的監管。

隨著監管機構對複方生物同源荷爾蒙療法的關注度不斷提高，一個深受尋求「天然」替代療法的消費者青睞的關鍵市場領域正面臨威脅。衛生部門已對複方製劑的效力不穩定、缺乏標準化劑量以及安全性數據不足表示擔憂。生產設施面臨更嚴格的檢測要求，而關於其療效與FDA核准治療方法的比較的行銷聲明也受到更嚴格的限制。限制複方荷爾蒙供應的監管措施可能會擾亂供應鏈和消費者獲取途徑，從而可能迫使患者轉向傳統藥物治療。然而，這可能造成市場不確定性，進而影響整個更年期支持產品領域的研發投資。

新冠疫情的影響：

新冠疫情透過降低醫療服務可近性和改變人們的健康優先事項，對更年期支持市場動態產生了影響。封鎖措施限制了常規婦科就診，並延誤了新診斷和治療的啟動。遠端醫療的普及在一定程度上緩解了這些干擾，導致更年期管理線上諮詢量顯著增加。疫情期間的壓力和生活方式的改變加劇了許多女性的更年期症狀，增加了潛在需求。供應鏈中斷影響了某些產品的供應，尤其是需要低溫運輸儲存的產品。在疫情後的恢復階段，遠端醫療在更年期照護的應用仍在持續，消費者對自我管理健康解決方案的興趣也日益濃厚。

在預測期內，口服劑型預計將佔據最大的市場佔有率。

預計在預測期內，口服劑型將佔據最大的市場佔有率，這主要得益於患者對其劑型的熟悉度、給藥便利性以及豐富的產品選擇。片劑和膠囊是荷爾蒙療法、營養補充劑和更年期症狀草藥療法的傳統劑型。口服製劑具有成熟的生產流程，可確保劑量精準、保存期限穩定且品質始終如一。消費者偏好便利、便攜的日常用藥方式，因此口服給藥優於侵入性較強的給藥途徑。製藥公司正不斷研發新型口服給藥技術，以提高生物利用度並減少胃腸道副作用。

在預測期內，補丁細分市場預計將呈現最高的複合年成長率。

在預測期內，貼片市場預計將呈現最高的成長率。其主要特徵包括經經皮吸收持續釋放激素，避免首過效應。貼片能穩定緩解症狀，避免口服藥物劑量波動帶來的不便，因此深受尋求療效可預測的女性歡迎。每週一次的用藥方案也十分便捷，無需每日服藥。越來越多的臨床證據表明，與口服藥物相比，經皮雌激素在心血管和血栓栓塞風險方面更具安全性，這促使醫生更建議使用貼片。產品創新包括更小巧、更隱密、黏著性更強、皮膚刺激性更低的貼劑，從而提高了不同患者群體的接受度和依從性。

市佔率最大的地區：

在預測期內，北美預計將保持最大的市場佔有率，這得益於較高的醫療保健意識、完善的醫藥基礎設施以及對女性健康的積極態度。廣泛的消費者廣告提高了女性對治療方案的了解，而全面的保險覆蓋則改善了她們獲得治療的機會。主要市場公司在全部區域設有總部和生產設施，確保了穩定的產品供應。強大的臨床研究基礎設施產生了大量的安全性和有效性數據，為醫生的處方決策提供支援。專業醫學協會積極發布更年期管理指南，促進治療方法和適當治療性介入的標準化。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要受人口快速老化、醫療保健支出增加以及社會觀念轉變的驅動。日本、中國和韓國等國家正經歷顯著的人口結構變化，包括更年期女性人口的成長。可支配收入的增加使得人們更容易獲得高品質的藥品和保健產品。傳統醫學體系中融入的草藥療法正在促進人們對更年期輔助產品的自然接受。西方製藥公司正透過與當地經銷商建立策略合作夥伴關係，日益瞄準這些市場。醫療保健教育措施正在提升醫療服務提供者的知識水平，而媒體討論也逐漸消除圍繞更年期的文化偏見。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 主要國家的市場估算和預測，以及根據客戶需求量身定做的複合年成長率（註：需要進行可行性測試）。
  • 競爭性標竿分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球更年期支持市場：依支持類型分類

  • 荷爾蒙療法
    • 雌激素療法
    • 聯合荷爾蒙療法
    • 黃體素療法
  • 非荷爾蒙療法
    • 處方箋非荷爾蒙藥物
    • 非處方非荷爾蒙產品
  • 營養補充品
    • 草藥補充劑
    • 維生素和礦物質
    • 植物雌激素
    • 歐米伽脂肪酸
    • 益生菌
    • 複合補充劑
  • 生活方式和健康解決方案
    • 健身和體重管理
    • 營養計劃
    • 心理健康和壓力管理
    • 睡眠支持解決方案
  • 醫療設備和數位療法
    • 骨盆底健康設備
    • 穿戴式健康監測
    • 女性科技平台
    • 遠端醫療和數位護理平台

第6章：全球更年期支持市場：依症狀類型分類

  • 血管舒縮症狀
  • 睡眠障礙
  • 情緒和認知症狀
  • 陰道和泌尿生殖系統症狀
  • 骨骼健康與骨質疏鬆症
  • 代謝和心血管問題
  • 性功能和性慾
  • 其他症狀

第7章：全球更年期支持市場：依給藥途徑分類

  • 口服
  • 局部和經皮吸收
  • 注射藥物
  • 陰道內給藥系統

第8章：全球更年期支持市場：以劑型分類

  • 片劑和膠囊
  • 軟凝膠
  • 粉末
  • 液體和滋補品
  • 修補
  • 乳霜和凝膠
  • 環和植入

第9章：全球更年期支持市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 診斷中心
  • 居家醫療環境
  • 健康中心及婦科診所

第10章 全球更年期支援市場：依通路分類

  • 醫院和診所
  • 零售藥局和藥房
  • 網路藥局和電子商務
  • 專賣店
  • 面向消費者的直銷平台

第11章 全球更年期支持市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Bayer AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Theramex
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK plc
  • Nature's Way Products, LLC
  • Holland & Barrett Retail Limited
  • Bonafide Health, LLC
  • Metagenics, Inc.
  • Blackmores Limited
Product Code: SMRC34225

According to Stratistics MRC, the Global Menopause Support Market is accounted for $18.3 billion in 2026 and is expected to reach $32.0 billion by 2034 growing at a CAGR of 7.2% during the forecast period. Menopause support products encompass pharmaceutical treatments, dietary supplements, and therapeutic delivery systems designed to alleviate symptoms associated with perimenopause and menopause, including hot flashes, mood disturbances, and vaginal atrophy. The market addresses the health needs of the growing aging female population through diverse administration routes and dosage formats. Increasing awareness about menopause management and declining stigma around discussing this life stage are driving product innovation and expanding treatment accessibility across global healthcare systems.

Market Dynamics:

Driver:

Growing aging female population worldwide

Demographic trends show a significant increase in women aged 45-60 globally, creating an expanding addressable market for menopause support solutions. Longer life expectancy means women spend approximately one-third of their lives in post-menopausal phases, intensifying focus on quality of life during these years. Healthcare systems increasingly recognize menopause as a medical concern requiring comprehensive management rather than an inevitable decline. This demographic shift, combined with rising disposable incomes among mature consumers, generates sustained demand for both pharmaceutical interventions and natural support products addressing symptom management and long-term health preservation.

Restraint:

Social stigma and underreporting of symptoms

Cultural taboos surrounding menopause continue to limit market expansion by discouraging open discussions between women and healthcare providers. Many women endure symptoms silently, unaware of available treatment options or reluctant to seek medical assistance due to embarrassment. This communication gap results in significant underdiagnosis and undertreatment, particularly in regions where aging and female health topics remain sensitive. Healthcare provider training often inadequately addresses menopause management, further contributing to low treatment rates. Breaking these cultural barriers requires sustained educational efforts targeting both consumers and medical professionals across diverse global markets.

Opportunity:

Personalized medicine and digital health integration

Advances in genetic testing and biomarker analysis enable tailored menopause treatment approaches based on individual symptom profiles and health histories. Digital health platforms offering symptom tracking, telehealth consultations, and personalized supplement recommendations create new engagement channels with consumers seeking customized solutions. Wearable devices monitoring sleep patterns, skin temperature, and heart rate variability provide objective data for treatment optimization. This convergence of personalized medicine and digital tools allows companies to develop direct-to-consumer relationships, gather real-world evidence on product efficacy, and create subscription-based models ensuring ongoing customer engagement beyond initial product purchase.

Threat:

Regulatory scrutiny of bioidentical hormones

Increasing regulatory attention on compounded bioidentical hormone therapies threatens a significant market segment favored by consumers seeking "natural" alternatives. Health authorities express concerns about inconsistent potency, lack of standardized dosing, and insufficient safety data for custom-compounded preparations. Manufacturing facilities face intensified inspection requirements, while marketing claims face greater restrictions regarding efficacy comparisons to FDA-approved therapies. Regulatory actions limiting compounded hormone availability could disrupt supply chains and consumer access, potentially driving patients toward conventional pharmaceutical options but creating market uncertainty that impacts investment in product development across the menopause support category.

Covid-19 Impact:

The COVID-19 pandemic disrupted menopause support market dynamics through reduced healthcare access and shifting health priorities. Lockdowns limited routine gynecological visits, delaying new diagnoses and treatment initiations. Telehealth adoption partially offset these disruptions, with virtual consultations for menopause management increasing significantly. Stress and lifestyle changes during pandemic periods exacerbated menopausal symptoms for many women, increasing underlying demand. Supply chain interruptions affected availability of specific products, particularly those requiring cold chain storage. Post-pandemic recovery shows sustained telehealth utilization for menopause care and heightened consumer interest in self-managed wellness solutions.

The Oral segment is expected to be the largest during the forecast period

The Oral segment is expected to account for the largest market share during the forecast period, driven by patient familiarity, ease of administration, and extensive product availability. Tablets and capsules represent conventional dosage forms for hormone therapies, dietary supplements, and herbal remedies addressing menopausal symptoms. Oral formulations offer precise dosing, stable shelf lives, and established manufacturing processes ensuring consistent quality. Consumer preference for discrete, portable, and simple daily routines favors oral administration over more invasive alternatives. Pharmaceutical companies continue developing novel oral delivery technologies improving bioavailability and reducing gastrointestinal side effects.

The Patches segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Patches segment is predicted to witness the highest growth rate, offering consistent hormone delivery through transdermal absorption while avoiding first-pass liver metabolism. Patches provide steady symptom relief without oral medication fluctuations, appealing to women seeking predictable outcomes. Convenience factors include once-weekly application schedules eliminating daily dosing requirements. Growing clinical evidence supporting transdermal estrogen safety regarding cardiovascular and thromboembolic risks compared to oral alternatives drives physician recommendations. Product innovations include smaller, more discreet patches with improved adhesion and reduced skin irritation, expanding patient acceptance and compliance across diverse demographics.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high healthcare awareness, strong pharmaceutical infrastructure, and progressive attitudes toward women's health. Extensive direct-to-consumer advertising educates women about treatment options, while robust insurance coverage improves treatment accessibility. Major market players maintain headquarters and manufacturing facilities throughout the region, ensuring consistent product availability. Clinical research infrastructure generates extensive safety and efficacy data supporting physician prescribing confidence. Professional medical societies actively publish menopause management guidelines, standardizing treatment approaches and encouraging appropriate therapeutic interventions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly aging populations, increasing healthcare expenditure, and evolving social attitudes. Countries including Japan, China, and South Korea experience significant demographic shifts with growing cohorts of menopausal women. Rising disposable incomes enable access to premium pharmaceutical and wellness products. Traditional medicine systems incorporating herbal approaches to menopause create natural acceptance of support products. Western pharmaceutical companies increasingly target these markets through strategic partnerships with local distributors. Medical education initiatives improve healthcare provider knowledge, while media discussions gradually reduce cultural stigma surrounding menopause.

Key players in the market

Some of the key players in Menopause Support Market include Bayer AG, Pfizer Inc., AbbVie Inc., Theramex, Astellas Pharma Inc., Eli Lilly and Company, Novartis AG, Amgen Inc., Merck & Co., Inc., GSK plc, Nature's Way Products, LLC, Holland & Barrett Retail Limited, Bonafide Health, LLC, Metagenics, Inc., and Blackmores Limited.

Key Developments:

In February 2026, Bayer presented new real-world evidence from the CHAPTER and REALISE studies at the Menopause Society Annual Meeting, highlighting significant undertreatment in natural menopause and the high use of benzodiazepines for sleep disturbances.

In February 2026, Astellas announced that its non-hormonal drug Veozah (fezolinetant) met its primary endpoint in a Japanese Phase III study, paving the way for regulatory submission and market entry in Japan.

In October 2025, Bonafide released its "State of Menopause" report, revealing that 59% of women aged 40-49 had never heard of perimenopause before experiencing symptoms, driving the company's 2026 strategy toward hormone-free education and clinical-grade supplements.

Support Types Covered:

  • Hormonal Therapies
  • Non-Hormonal Therapies
  • Dietary Supplements
  • Lifestyle and Wellness Solutions
  • Medical Devices and Digital Therapeutics

Symptom Types Covered:

  • Vasomotor Symptoms
  • Sleep Disorders
  • Mood and Cognitive Symptoms
  • Vaginal and Urogenital Symptoms
  • Bone Health and Osteoporosis
  • Metabolic and Cardiovascular Concerns
  • Sexual Health and Libido
  • Other Symptoms

Route of Administrations Covered:

  • Oral
  • Topical and Transdermal
  • Injectable
  • Vaginal Delivery Systems

Dosage Forms Covered:

  • Tablets and Capsules
  • Softgels
  • Powders
  • Liquids and Tonics
  • Patches
  • Creams and Gels
  • Rings and Implants

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Homecare Settings
  • Wellness Centers and Gynecology Clinics

Distribution Channels Covered:

  • Hospitals and Clinics
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies and E-commerce
  • Specialty Stores
  • Direct-to-Consumer Platforms

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Menopause Support Market, By Support Type

  • 5.1 Hormonal Therapies
    • 5.1.1 Estrogen Therapy
    • 5.1.2 Combined Hormone Therapy
    • 5.1.3 Progesterone Therapy
  • 5.2 Non-Hormonal Therapies
    • 5.2.1 Prescription Non-Hormonal Drugs
    • 5.2.2 OTC Non-Hormonal Products
  • 5.3 Dietary Supplements
    • 5.3.1 Herbal Supplements
    • 5.3.2 Vitamins and Minerals
    • 5.3.3 Phytoestrogens
    • 5.3.4 Omega Fatty Acids
    • 5.3.5 Probiotics
    • 5.3.6 Combination Supplements
  • 5.4 Lifestyle and Wellness Solutions
    • 5.4.1 Fitness and Weight Management
    • 5.4.2 Nutrition Programs
    • 5.4.3 Mental Health and Stress Management
    • 5.4.4 Sleep Support Solutions
  • 5.5 Medical Devices and Digital Therapeutics
    • 5.5.1 Pelvic Health Devices
    • 5.5.2 Wearable Health Monitoring
    • 5.5.3 Femtech Platforms
    • 5.5.4 Telehealth and Digital Care Platforms

6 Global Menopause Support Market, By Symptom Type

  • 6.1 Vasomotor Symptoms
  • 6.2 Sleep Disorders
  • 6.3 Mood and Cognitive Symptoms
  • 6.4 Vaginal and Urogenital Symptoms
  • 6.5 Bone Health and Osteoporosis
  • 6.6 Metabolic and Cardiovascular Concerns
  • 6.7 Sexual Health and Libido
  • 6.8 Other Symptoms

7 Global Menopause Support Market, By Route of Administration

  • 7.1 Oral
  • 7.2 Topical and Transdermal
  • 7.3 Injectable
  • 7.4 Vaginal Delivery Systems

8 Global Menopause Support Market, By Dosage Form

  • 8.1 Tablets and Capsules
  • 8.2 Softgels
  • 8.3 Powders
  • 8.4 Liquids and Tonics
  • 8.5 Patches
  • 8.6 Creams and Gels
  • 8.7 Rings and Implants

9 Global Menopause Support Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Diagnostic Centers
  • 9.4 Homecare Settings
  • 9.5 Wellness Centers and Gynecology Clinics

10 Global Menopause Support Market, By Distribution Channel

  • 10.1 Hospitals and Clinics
  • 10.2 Retail Pharmacies and Drug Stores
  • 10.3 Online Pharmacies and E-commerce
  • 10.4 Specialty Stores
  • 10.5 Direct-to-Consumer Platforms

11 Global Menopause Support Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Bayer AG
  • 14.2 Pfizer Inc.
  • 14.3 AbbVie Inc.
  • 14.4 Theramex
  • 14.5 Astellas Pharma Inc.
  • 14.6 Eli Lilly and Company
  • 14.7 Novartis AG
  • 14.8 Amgen Inc.
  • 14.9 Merck & Co., Inc.
  • 14.10 GSK plc
  • 14.11 Nature's Way Products, LLC
  • 14.12 Holland & Barrett Retail Limited
  • 14.13 Bonafide Health, LLC
  • 14.14 Metagenics, Inc.
  • 14.15 Blackmores Limited

List of Tables

  • Table 1 Global Menopause Support Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Menopause Support Market Outlook, By Support Type (2023-2034) ($MN)
  • Table 3 Global Menopause Support Market Outlook, By Hormonal Therapies (2023-2034) ($MN)
  • Table 4 Global Menopause Support Market Outlook, By Estrogen Therapy (2023-2034) ($MN)
  • Table 5 Global Menopause Support Market Outlook, By Combined Hormone Therapy (2023-2034) ($MN)
  • Table 6 Global Menopause Support Market Outlook, By Progesterone Therapy (2023-2034) ($MN)
  • Table 7 Global Menopause Support Market Outlook, By Non-Hormonal Therapies (2023-2034) ($MN)
  • Table 8 Global Menopause Support Market Outlook, By Prescription Non-Hormonal Drugs (2023-2034) ($MN)
  • Table 9 Global Menopause Support Market Outlook, By OTC Non-Hormonal Products (2023-2034) ($MN)
  • Table 10 Global Menopause Support Market Outlook, By Dietary Supplements (2023-2034) ($MN)
  • Table 11 Global Menopause Support Market Outlook, By Herbal Supplements (2023-2034) ($MN)
  • Table 12 Global Menopause Support Market Outlook, By Vitamins and Minerals (2023-2034) ($MN)
  • Table 13 Global Menopause Support Market Outlook, By Phytoestrogens (2023-2034) ($MN)
  • Table 14 Global Menopause Support Market Outlook, By Omega Fatty Acids (2023-2034) ($MN)
  • Table 15 Global Menopause Support Market Outlook, By Probiotics (2023-2034) ($MN)
  • Table 16 Global Menopause Support Market Outlook, By Combination Supplements (2023-2034) ($MN)
  • Table 17 Global Menopause Support Market Outlook, By Lifestyle and Wellness Solutions (2023-2034) ($MN)
  • Table 18 Global Menopause Support Market Outlook, By Fitness and Weight Management (2023-2034) ($MN)
  • Table 19 Global Menopause Support Market Outlook, By Nutrition Programs (2023-2034) ($MN)
  • Table 20 Global Menopause Support Market Outlook, By Mental Health and Stress Management (2023-2034) ($MN)
  • Table 21 Global Menopause Support Market Outlook, By Sleep Support Solutions (2023-2034) ($MN)
  • Table 22 Global Menopause Support Market Outlook, By Medical Devices and Digital Therapeutics (2023-2034) ($MN)
  • Table 23 Global Menopause Support Market Outlook, By Pelvic Health Devices (2023-2034) ($MN)
  • Table 24 Global Menopause Support Market Outlook, By Wearable Health Monitoring (2023-2034) ($MN)
  • Table 25 Global Menopause Support Market Outlook, By Femtech Platforms (2023-2034) ($MN)
  • Table 26 Global Menopause Support Market Outlook, By Telehealth and Digital Care Platforms (2023-2034) ($MN)
  • Table 27 Global Menopause Support Market Outlook, By Symptom Type (2023-2034) ($MN)
  • Table 28 Global Menopause Support Market Outlook, By Vasomotor Symptoms (2023-2034) ($MN)
  • Table 29 Global Menopause Support Market Outlook, By Sleep Disorders (2023-2034) ($MN)
  • Table 30 Global Menopause Support Market Outlook, By Mood and Cognitive Symptoms (2023-2034) ($MN)
  • Table 31 Global Menopause Support Market Outlook, By Vaginal and Urogenital Symptoms (2023-2034) ($MN)
  • Table 32 Global Menopause Support Market Outlook, By Bone Health and Osteoporosis (2023-2034) ($MN)
  • Table 33 Global Menopause Support Market Outlook, By Metabolic and Cardiovascular Concerns (2023-2034) ($MN)
  • Table 34 Global Menopause Support Market Outlook, By Sexual Health and Libido (2023-2034) ($MN)
  • Table 35 Global Menopause Support Market Outlook, By Other Symptoms (2023-2034) ($MN)
  • Table 36 Global Menopause Support Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 37 Global Menopause Support Market Outlook, By Oral (2023-2034) ($MN)
  • Table 38 Global Menopause Support Market Outlook, By Topical and Transdermal (2023-2034) ($MN)
  • Table 39 Global Menopause Support Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 40 Global Menopause Support Market Outlook, By Vaginal Delivery Systems (2023-2034) ($MN)
  • Table 41 Global Menopause Support Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 42 Global Menopause Support Market Outlook, By Tablets and Capsules (2023-2034) ($MN)
  • Table 43 Global Menopause Support Market Outlook, By Softgels (2023-2034) ($MN)
  • Table 44 Global Menopause Support Market Outlook, By Powders (2023-2034) ($MN)
  • Table 45 Global Menopause Support Market Outlook, By Liquids and Tonics (2023-2034) ($MN)
  • Table 46 Global Menopause Support Market Outlook, By Patches (2023-2034) ($MN)
  • Table 47 Global Menopause Support Market Outlook, By Creams and Gels (2023-2034) ($MN)
  • Table 48 Global Menopause Support Market Outlook, By Rings and Implants (2023-2034) ($MN)
  • Table 49 Global Menopause Support Market Outlook, By End User (2023-2034) ($MN)
  • Table 50 Global Menopause Support Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 51 Global Menopause Support Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 52 Global Menopause Support Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 53 Global Menopause Support Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 54 Global Menopause Support Market Outlook, By Wellness Centers and Gynecology Clinics (2023-2034) ($MN)
  • Table 55 Global Menopause Support Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 56 Global Menopause Support Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 57 Global Menopause Support Market Outlook, By Retail Pharmacies and Drug Stores (2023-2034) ($MN)
  • Table 58 Global Menopause Support Market Outlook, By Online Pharmacies and E-commerce (2023-2034) ($MN)
  • Table 59 Global Menopause Support Market Outlook, By Specialty Stores (2023-2034) ($MN)
  • Table 60 Global Menopause Support Market Outlook, By Direct-to-Consumer Platforms (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.